Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) EPS (Weighted Average and Diluted) (2021 - 2026)

C4 Therapeutics has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.2 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 45.95% year-over-year to -$0.2; the TTM value through Mar 2026 reached -$1.1, up 25.17%, while the annual FY2025 figure was -$1.27, 16.45% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.2 at C4 Therapeutics, down from -$0.09 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at -$0.09 in Q4 2025 and troughed at -$0.76 in Q4 2022.
  • A 5-year average of -$0.49 and a median of -$0.49 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 145.16% in 2022 and later soared 81.63% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.76 in 2022, then grew by 10.53% to -$0.68 in 2023, then increased by 27.94% to -$0.49 in 2024, then soared by 81.63% to -$0.09 in 2025, then plummeted by 122.22% to -$0.2 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CCCC at -$0.2 in Q1 2026, -$0.09 in Q4 2025, and -$0.44 in Q3 2025.